https://www.thefdalawblog.com/2026/10/six-month-window-doj-and-hhs-launch-healthcare-fca-self-disclosure-pilot/?utm_source=rss&utm_medium=rss&utm_campaign=six-month-window-doj-and-hhs-launch-healthcare-fca-self-disclosure-pilot
On October 22, 2026, the DOJ Civil Division and the Department of Health and Human Services (HHS) announced a six-month pilot program that offers “legitimate American healthcare businesses” a defined path to come clean on potential False Claims Act (FCA) violations, in exchange for a coordinated civil release and a repayment within a set multiplier range. This False Claims Act Self-Disclosure Pilot Program, or FCA SDPP for short, comes on the heels of recent pronouncements from DOJ about prioritizing criminal healthcare fraud enforcement and from HHS about granting CMS parallel exclusion authority; for more detail, see our posts here and here. The stated goal of this latest self-disclosure program is to allow companies to quickly move forward with a clean slate on civil FCA liability, rather than undergo years of investigation and negotiation. But, as discussed further below, this program has some serious limitations that life sciences companies must consider carefully.
No hay comentarios:
Publicar un comentario